Older female mice given semaglutide late in life had a median lifespan of 834 days—about 12% longer than untreated controls—but the result does not show that Ozempic or Wegovy slows aging in people.

Published: September 3, 2026, 9:26 p.m. PKT · Reporting cutoff: September 3, 2026, 9:15 p.m. PKT

What you need to know

  • Researchers treated 20-month-old female C57BL/6 mice with semaglutide, a GLP-1 receptor agonist.
  • Median lifespan was 834 days in treated mice versus 742 days in untreated controls, a difference of roughly 12%.
  • Treated mice ate about 24% less and showed improvements in several measures of physical function, glucose control and spatial memory.
  • A matched calorie-restriction comparison suggests that reduced food intake did not explain every biological change observed.
  • This was one experiment in older female mice of one inbred strain; it provides no evidence that semaglutide extends human lifespan.

Semaglutide has changed the treatment of diabetes and obesity. Now a controlled experiment has found that the drug also lengthened life in older female mice and softened several age-related changes. The finding is scientifically provocative because some effects persisted after researchers compared the animals with mice eating similarly fewer calories.

It is not an anti-aging prescription. Mouse longevity results frequently fail to translate to people, and semaglutide has known risks that require medical supervision.

What the semaglutide aging study found

The researchers began treatment when the mice were 20 months old, an advanced age for the species. After three months, treated animals performed better on tests of coordination and muscle function, processed glucose more effectively and showed improved spatial memory. Continued treatment was associated with a median lifespan increase from 742 to 834 days.

The team also examined molecular features associated with aging. Semaglutide altered nutrient-sensing pathways and gene activity related to inflammation, lipid metabolism, immune response, DNA repair and glucose regulation. These are biological signals, not proof that aging as a whole was reversed.

Was the effect only caused by eating less?

Semaglutide-treated mice consumed about 24% less food. Calorie restriction can extend lifespan in several laboratory organisms, so reduced intake is an obvious alternative explanation.

To separate the effects, the researchers included a calorie-restricted comparison group matched to the lower food intake. Some physiological and molecular changes overlapped, while others differed, suggesting that semaglutide may act through more than appetite reduction alone. That distinction matters because it creates testable hypotheses about GLP-1 signaling, inflammation and cellular maintenance.

Why this does not mean Ozempic extends human life

A controlled mouse experiment can reveal mechanisms and justify further research, but it cannot predict a person’s lifespan. The animals shared sex, strain, laboratory conditions and treatment timing. Human aging unfolds across far more genetic, environmental and medical variation.

Ozempic and Wegovy contain semaglutide but are approved for specific metabolic indications, not life extension. The study does not support taking or changing the drug for longevity. Anyone considering a GLP-1 medicine should discuss its approved benefits and risks with a qualified clinician.

For broader biological context, SciQuest’s guide to the world’s longest-living animals explores the very different strategies associated with longevity across species.

How other headlines framed it

  • Nature News asked whether GLP-1 drugs can slow aging while foregrounding that the evidence comes from mice.
  • Scientific American emphasized the possible aging implications of GLP-1 medication.
  • Chemical & Engineering News focused on the mouse-longevity result and its biological mechanism.

What scientists need to test next

Replication in male mice, genetically varied animals and different dosing schedules would show how robust the result is. Human studies would need long follow-up and clinically meaningful outcomes—not only biomarkers—to determine whether any effect extends healthy life.

Bottom line: Semaglutide extended lifespan and improved several late-life measures in one controlled mouse study. That makes aging biology a serious research question for GLP-1 drugs, not an established human benefit.

Sources

  1. Feng and colleagues, “Late-life semaglutide treatment slows ageing and extends lifespan in female mice,” Nature, September 2, 2026.
  2. Nature News, “Can GLP-1 drugs slow ageing? Mouse study shows promise,” September 2, 2026.
  3. NIH/EurekAlert research summary.

Editorial disclosure: The lead image is an original concept illustration, not a study photograph. SciQuest received no payment for this coverage. This article provides scientific reporting, not medical advice. To report a possible error, contact SciQuest.